| Enhance
Biotech Inc. Announces Successful Completion
of Phase IIa Trial In Premature Ejaculation
January
27, 2004
NEW YORK, January 27 /PRNewswire/ -- Enhance
Biotech Inc., (OTC Bulletin Board: EBOI) announced
today the successful completion of a 30 patient
Phase IIa trial of their product LI 301 for
premature ejaculation. This condition is widely
recognised to be as large a market as the well
established multi-billion dollar erectile
dysfunction area that currently has blockbuster
drugs at market such as Pfizer's Viagra,
Glaxo's Levitra, and Eli Lilly's Cialis. However,
this market has not received the same attention
from drug developers as yet in spite of affecting
some 29% of the male population at some time
in their life and having a significant impact
on relationships in couples trying to cope with
its effects.
The trial was run in Europe in collaboration
with an international contract research organization
(CRO) with a placebo controlled, double blind
randomised cross over design. The compound LI
301, which has a unique mode of action in this
condition, successfully met the endpoint demonstrating
substantial effect against the placebo. With
the successful results achieved, multi-centre
trails are now being prepared.
Chris Every, CEO of Enhance
said, "We are delighted to have achieved
this confirmation of effect enabling us to move
on to extensive further trials. We have taken
a unique approach in treating this condition
by not following the other compounds being developed
in this field that are currently achieving mixed
results working chiefly with serotonin reuptake
inhibitors. We believe the trial results achieved
demonstrate a real opportunity to have a successful
drug at market in a blockbuster sector where
there are currently no other approved treatments."
About Enhance Biotech
Enhance Biotech Inc. is developing
a product portfolio focused upon two key areas
of lifestyle drug development; Sexual Dysfunction
conditions and Dermatological indications. Within
those two areas the key conditions are; Sexual
Dysfunctions, including Premature Ejaculation
and Male Fertility and Dermatological Indications,
including Cellulite, Anti-aging and Skin Disorders
covering Atopic Dermatitis and Psoriasis. Enhance's
products are each licensed in at pre-clinical
or Phase I stages. They are being taken on through
development and approval to market mainly through
licensing partnerships with suitable partners
for each product area whilst adding significant
value to each in the immediate future. This
creates a valuable product pipeline portfolio
in a market forecast at conservative estimates
to grow to US$32 billion by 2008. The pharmaceutical
industry has invested over $20 billion in R&D
for lifestyle drugs in the last ten years, although
relatively few new products have as yet reached
the market. Enhance's lead development products
fill unmet needs in global blockbuster markets.
The Management and Science Team have a proven
track record of successful development and commercialization
of new products and the licensing out of valuable
intellectual property. For more information
on the Company please see the Company's website
at www.enhancelifesciences.com .
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private
Securities Litigation Reform Act of 1995). Because
these statements include risks and uncertainties,
actual results may differ materially from those
expressed or implied by such forward-looking
statements. Specifically, factors that could
cause actual results to differ materially from
those expressed or implied by such forward-looking
statements include, but are not limited to:
risks associated with preclinical and clinical
developments in the biopharmaceutical industry
in general and in Enhance Biotech's compounds
under development in particular; the potential
failure of Enhance Biotech's compounds under
development to prove safe and effective for
treatment of disease; uncertainties inherent
in the early stage of Enhance Biotech' compounds
under development; failure to successfully implement
or complete clinical trials; failure to receive
marketing clearance from regulatory agencies
for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic
initiatives that change Enhance Biotech' business,
structure or projections; the development of
competing products; uncertainties related to
Enhance Biotech' dependence on third parties
and partners; and those risks described in the
filings with the SEC, all of which are under
the Company's prior name Becor Communications,
Inc. The Company and Enhance Biotech disclaim
any obligation to update these forward-looking
statements.
Contact:
Laurel Moody
Sky Investor Relations
+1 212-440-5000
laurel@skyir.com
Web site: http://www.enhancelifesciences.com
Distributed by PR Newswire on behalf of Enhance
Biotech Inc.
source:-http://www.prnewswire.co.uk
|
|
